CXCR3 and neoplasm: The same group later reported that single-agent administration of another novel STING agonist (ADU-S100) decreased tumor burden and activated the murine immune system by increasing CTL tumor infiltration and decreasing TAMs and Tregs in a CXCR3-dependent fashion [210].